PubMed Journals Articles About "ImmunityBio Granted Breakthrough Therapy Designation Superagonist Muscle Invasive" RSS

18:37 EST 26th January 2020 | BioPortfolio

ImmunityBio Granted Breakthrough Therapy Designation Superagonist Muscle Invasive PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest ImmunityBio Granted Breakthrough Therapy Designation Superagonist Muscle Invasive articles that have been published worldwide.

More Information about "ImmunityBio Granted Breakthrough Therapy Designation Superagonist Muscle Invasive" on BioPortfolio

We have published hundreds of ImmunityBio Granted Breakthrough Therapy Designation Superagonist Muscle Invasive news stories on BioPortfolio along with dozens of ImmunityBio Granted Breakthrough Therapy Designation Superagonist Muscle Invasive Clinical Trials and PubMed Articles about ImmunityBio Granted Breakthrough Therapy Designation Superagonist Muscle Invasive for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ImmunityBio Granted Breakthrough Therapy Designation Superagonist Muscle Invasive Companies in our database. You can also find out about relevant ImmunityBio Granted Breakthrough Therapy Designation Superagonist Muscle Invasive Drugs and Medications on this site too.

Showing "ImmunityBio Granted Breakthrough Therapy Designation Superagonist Muscle Invasive" PubMed Articles 1–25 of 18,000+

Discovering therapeutic protein targets for muscle invasive bladder cancer by proteomic data analysis.

Bladder cancer accounts for almost 54% of urinary system cancer and is the second most frequent cause of death in genitourinary malignancies after prostate cancer. About 70% of bladder tumors are non-muscle-invasive, and the rest are muscle-invasive. Recurrence of the tumor is the common feature of bladder cancer. Chemotherapy is a conventional treatment for MIBC, but it cannot improve the survival rate of these patients sufficiently. Therefore, researchers must develop new therapies. Antibody-based therapy...

The updated outcomes of bladder-preserving trimodal therapy using a real-time tumor-tracking radiotherapy system for patients with muscle-invasive bladder cancer.

Bladder-preserving trimodal therapy is recognized as a promising alternative treatment for muscle-invasive bladder cancer. We report the updated outcomes of muscle-invasive bladder cancer patients that were treated using our treatment protocol, which involves radiotherapy delivered with a real-time tumor-tracking radiotherapy system.

Outcomes of trimodality bladder-sparing therapy for muscle-invasive bladder cancer.

Although radical cystectomy is considered the standard of care for muscle-invasive bladder cancer (MIBC), recent data has suggested comparable survival outcomes for bladder-sparing trimodality therapy (TMT). We conducted a retrospective, single-institution analysis of MIBC patients to evaluate the efficacy of TMT as an alternative, curative approach to surgical intervention.

Advancing RAS/RASopathy therapies: An NCI-sponsored intramural and extramural collaboration for the study of RASopathies.

RASopathies caused by germline pathogenic variants in genes that encode RAS pathway proteins. These disorders include neurofibromatosis type 1 (NF1), Noonan syndrome (NS), cardiofaciocutaneous syndrome (CFC), and Costello syndrome (CS), and others. RASopathies are characterized by heterogenous manifestations, including congenital heart disease, failure to thrive, and increased risk of cancers. Previous work led by the NCI Pediatric Oncology Branch has altered the natural course of one of the key manifestati...

Chemoradiation Versus Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Propensity Score-Weighted Comparative Analysis Using the National Cancer Database.

To address the overarching question whether chemoradiation therapy (CMT) offers overall survival (OS) similar to that of radical cystectomy (RC) in muscle-invasive bladder cancer (MIBC), we performed analyses using the National Cancer Database (NCDB).

Defining Breakthrough Invasive Fungal Infection- Position Paper of the Mycoses Study Group Education and Research Consortium (MSG-ERC) and the European Confederation of Medical Mycology (ECMM).

Breakthrough invasive fungal infections (IFI) have emerged as a significant problem in patients receiving systemic antifungals; however, consensus criteria for defining breakthrough IFI are missing. This position paper establishes broadly applicable definitions of breakthrough IFI for clinical research. Representatives of the Mycoses Study Group Education and Research Consortium (MSG-ERC) and the European Confederation of Medical Mycology (ECMM) reviewed the relevant English literature for definitions appli...

Comparison of Two NIRS Tissue Oximeters (Moxy and Nimo) for Non-Invasive Assessment of Muscle Oxygenation and Perfusion.

Near-infrared spectroscopy (NIRS) tissue oximeters enable non-invasive measurement of muscle oxygenation and perfusion. Several NIRS oximeters are currently available, particularly for muscle measurements.

A rare case of multi-focal human TB after BCG instillation for non-muscle-invasive bladder cancer.

To describe a left epididymitis and para-aortical involvement caused by reactivation after bacillus Calmette-Guérin instillation for non-muscle-invasive bladder cancer.

Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy of Non-muscle Invasive Bladder Cancer.

Rescue intravesical therapies for BCG failure non-muscle invasive bladder cancer (NMIBC) patients remain a critical focus of ongoing research. Sequential intravesical gemcitabine and docetaxel (Gem/Doce) has shown safety and efficacy in 2 retrospective, single institution cohorts. This doublet has since been adopted as an intravesical salvage option at multiple institutions. We now report the results of a multi-institutional evaluation of Gem/Doce.

A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.

Muscle-invasive bladder cancer (MIBC) is a molecularly diverse disease with heterogeneous clinical outcomes. Several molecular classifications have been proposed, but the diversity of their subtype sets impedes their clinical application.

Development and Initial Testing of a Modified UroVysion-Based Fluorescence In Situ Hybridization Score for Prediction of Progression in Bladder Cancer.

Our aim was to predict progression of non-muscle-invasive bladder urothelial carcinomas (NMIUCs) into muscle-invasive disease by assessing cytogenetic abnormality of tumors with a new UroVysion scoring system.

Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non-muscle-invasive Bladder Cancer.

The purpose of this study was to compare the efficacy of 2 bacillus Calmette-Guérin (BCG) strains, BCG-Tice and BCG-Moreau, in the treatment of non-muscle-invasive bladder cancer (NMIBC).

Editorial Comment from Dr Kobayashi to Renal function after bladder-preserving therapy for patients with muscle-invasive bladder cancer: Results of selective bladder-preserving tetramodality therapy consisting of maximal transurethral resection, induction chemoradiotherapy and partial cystectomy.

Health-Related Quality of Life among Non-Muscle-Invasive Bladder Cancer Survivors: A Population-Based Study.

To examine the effect of non-muscle-invasive bladder cancer (NMIBC) diagnosis and treatment on survivors' quality of life (QOL).

Update on the Guideline of Guidelines: Non-Muscle Invasive Bladder Cancer.

Non-muscle invasive bladder cancer (NMIBC) is the most common form of bladder cancer with frequent recurrences and risk for progression. Risk stratified treatment and surveillance protocols are often utilized to guide management. In 2017, this journal reviewed guidelines on NMIBC from four major organizations: the American Urological Association (AUA)/ Society of Urologic Oncology (SUO), the European Association of Urology (EAU), the National Comprehensive Cancer Network (NCCN), and the National Institute f...

Validation of the Dutch version of the Breakthrough Pain Assessment Tool in Patients with Cancer.

Essential for adequate management of breakthrough cancer pain is a combination of accurate (re-)assessment and a personalized treatment plan. The Breakthrough pain Assessment Tool (BAT) has been proven to be a brief, multidimensional, reliable and valid questionnaire for the assessment of breakthrough cancer pain.

Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers.

Patients with residual muscle-invasive urinary tract cancer after neoadjuvant chemotherapy (NAC) have a high risk of recurrence.

The Natural History of Untreated Muscle Invasive Bladder Cancer.

To describe the natural history of untreated muscle invasive bladder cancer (MIBC) and compare the oncological outcomes of treated and untreated patients.

A single-institute experience of trimodal bladder-preserving therapy for histologic variants of urothelial carcinoma.

We retrospectively evaluated the clinical outcomes of patients with histologic variants of muscle invasive bladder cancer (MIBC) treated with trimodal bladder-preserving therapy (TMT).

Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer.

The sarcomatoid morphology of muscle-invasive bladder cancer (MIBC) is associated with unfavorable prognosis. However, the genomic, transcriptomic, and proteomic relationship between conventional urothelial and synchronous sarcomatoid morphology is poorly defined.

Buccal opioids for breakthrough pain in children with life-limiting conditions receiving end-of-life care.

Many palliative care health settings that care for children and young people (CYP) at the end of life use the buccal mucosa as a route of drug administration to manage the sudden onset of symptoms, such as seizures, agitation and dyspnoea, and for breakthrough pain management. The buccal route is a minimally invasive method that delivers fast symptom relief and is useful for those with swallowing impairment or reduced enteral absorption.

Estimating the optimal perioperative chemotherapy utilization rate for muscle-invasive bladder cancer.

Identifying optimal chemotherapy (CT) utilization rates can drive improvements in quality of care. We report a benchmarking approach to estimate the optimal rate of perioperative CT for muscle-invasive bladder cancer (MIBC).

Is the En Bloc Transurethral Resection More Effective than Conventional Transurethral Resection for Non-Muscle-Invasive Bladder Cancer? A Systematic Review and Meta-Analysis.

En bloc transurethral resection (ERBT) is a major topic of discussion as an alternative to conventional transurethral resection (cTURBT) for the treatment of non-muscle-invasive bladder cancer (NMIBC) addressing the limitations of cTURBT.

Cardiorespiratory Physiology following Minimally Invasive Surfactant Therapy in Preterm Infants.

Surfactant replacement therapy through the endotracheal tube has been shown to improve lung compliance and reduce pulmonary pressures. Minimally invasive surfactant therapy (MIST) combines the benefits of continuous positive airway pressure (CPAP) and surfactant for spontaneously breathing preterm infants. We aimed to characterize the haemodynamic changes accompanying the first dose of MIST in preterm infants.

Clinical Complete Response after Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Call for Standardized Assessments and Definitions.

The ability to accurately determine a complete clinical response (cCR) to neoadjuvant chemotherapy (NAC) before cystectomy could have paradigm-shifting implications for the management of muscle-invasive bladder cancer. Level 1 evidence demonstrates that up to 40% of patients are downstaged to pT0 disease following NAC, presenting an intriguing opportunity to identify select patients who might be spared the morbidity of radical surgery. However, clinical investigations in this space are hindered by lack of a...

Quick Search